6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Commonly	RB	commonly	commonly	commonli	N	O
observed	VBD	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
information	NN	information	information	inform	N	O
below	NN	below	below	below	N	O
is	VBZ	is	is	is	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
database	NN	database	database	databas	N	O
for	IN	for	for	for	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
2070	CD	2070	2070	2070	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
,	,	,	,	,	N	O
806	CD	806	806	806	N	O
received	VBD	received	received	receiv	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
463	CD	463	463	463	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
were	VBD	were	were	were	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
multiple	JJ	multiple	multiple	multipl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
conditions	NNS	conditions	condition	condit	N	O
and	CC	and	and	and	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
varied	VBD	varied	varied	vari	N	O
greatly	RB	greatly	greatly	greatli	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
overlapping	VBG	overlapping	overlapping	overlap	N	O
categories	NNS	categories	category	categori	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
and	CC	and	and	and	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
phases	NNS	phases	phase	phase	N	O
of	IN	of	of	of	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
inpatients	NNS	inpatients	inpatient	inpati	N	O
and	CC	and	and	and	N	O
outpatients	NNS	outpatients	outpatient	outpati	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
and	CC	and	and	and	N	O
longer	JJR	longer	longer	longer	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
during	IN	during	during	dure	N	O
exposure	NN	exposure	exposure	exposur	N	O
were	VBD	were	were	were	N	O
obtained	VBN	obtained	obtained	obtain	N	O
by	IN	by	by	by	N	O
general	JJ	general	general	gener	N	O
inquiry	NN	inquiry	inquiry	inquiri	N	O
and	CC	and	and	and	N	O
recorded	VBN	recorded	recorded	record	N	O
by	IN	by	by	by	N	O
clinical	JJ	clinical	clinical	clinic	N	O
investigators	NNS	investigators	investigator	investig	N	O
using	VBG	using	using	use	N	O
their	PRP$	their	their	their	N	O
own	JJ	own	own	own	N	O
terminology	NN	terminology	terminology	terminolog	N	O
.	.	.	.	.	N	O

Consequently	RB	consequently	consequently	consequ	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
provide	VB	provide	provide	provid	N	O
a	DT	a	a	a	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
estimate	NN	estimate	estimate	estim	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
individuals	NNS	individuals	individual	individu	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
grouped	VBN	grouped	grouped	group	N	O
in	IN	in	in	in	N	O
standardized	JJ	standardized	standardized	standard	N	O
categories	NNS	categories	category	categori	N	O
using	VBG	using	using	use	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
terminology	NN	terminology	terminology	terminolog	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
stated	JJ	stated	stated	state	N	O
frequencies	NNS	frequencies	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
represent	VBP	represent	represent	repres	N	O
the	DT	the	the	the	N	O
proportions	NNS	proportions	proportion	proport	N	O
of	IN	of	of	of	N	O
individuals	NNS	individuals	individual	individu	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
type	NN	type	type	type	N	O
listed	VBN	listed	listed	list	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
considered	VBN	considered	considered	consid	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
if	IN	if	if	if	N	O
it	PRP	it	it	it	N	O
occurred	VBD	occurred	occurred	occur	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
time	NN	time	time	time	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
therapy	NN	therapy	therapy	therapi	N	O
following	VBG	following	following	follow	N	O
baseline	JJ	baseline	baseline	baselin	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
information	NN	information	information	inform	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
sections	NNS	sections	section	section	N	O
was	VBD	was	wa	wa	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
daily	JJ	daily	daily	daili	N	O
doses	NNS	doses	dos	dose	N	O
within	IN	within	within	within	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
874	CD	874	874	874	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
among	IN	among	among	among	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
More	JJR	more	more	more	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
enumerates	VBZ	enumerates	enumerates	enumer	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
spontaneously	RB	spontaneously	spontaneously	spontan	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
listing	VBG	listing	listing	list	N	O
those	DT	those	those	those	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
dose	JJ	dose	dose	dose	N	O
group	NN	group	group	group	N	O
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Emergent	JJ	emergent	emergent	emerg	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Short	NNP	short	short	short	N	O
-	:	-	-	-	N	O
Term	NNP	term	term	term	N	O
,	,	,	,	,	N	O
Fixed	NNP	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
Flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
Dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
or	CC	or	or	or	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Dictionary	NNP	dictionary	dictionary	dictionari	N	O
-	:	-	-	-	N	O
derived	JJ	derived	derived	deriv	N	O
Term	NNP	term	term	term	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
483	CD	483	483	483	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
391	CD	391	391	391	N	O
)	)	)	)	)	N	O

Body	NN	body	body	bodi	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
Whole	JJ	whole	whole	whole	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
6	CD	6	6	6	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
Stiffness	NNP	stiffness	stiffness	stiff	Y	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
Increased	VBD	increased	increased	increas	N	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
9	CD	9	9	9	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
12	CD	12	12	12	N	O

Eye	NN	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Vision	NN	vision	vision	vision	N	B-AdverseReaction
Blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
8	CD	8	8	8	N	O
7	CD	7	7	7	N	O
10	CD	10	10	10	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
Mouth	NNP	mouth	mouth	mouth	N	I-AdverseReaction
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
10	CD	10	10	10	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
7	CD	7	7	7	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
Discomfort	NNP	discomfort	discomfort	discomfort	Y	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Infections	NNS	infections	infection	infect	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
7	CD	7	7	7	N	O
10	CD	10	10	10	N	O
20	CD	20	20	20	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
5	CD	5	5	5	N	O
9	CD	9	9	9	N	O
15	CD	15	15	15	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
Disorder	NNP	disorder	disorder	disord	N	I-AdverseReaction
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Tremor	NNP	tremor	tremor	tremor	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Lethargy	NNP	lethargy	lethargy	lethargi	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
System	NN	system	system	system	N	O

Ejaculation	NNP	ejaculation	ejaculation	ejacul	N	B-AdverseReaction
Failure	NNP	failure	failure	failur	N	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Respiratory	NN	respiratory	respiratory	respiratori	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
Congestion	NNP	congestion	congestion	congest	N	I-AdverseReaction
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
8	CD	8	8	8	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Skin	NN	skin	skin	skin	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
Hypotension	NNP	hypotension	hypotension	hypotens	Y	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Table	JJ	table	table	tabl	N	O
includes	VBZ	includes	includes	includ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
dose	NN	dose	dose	dose	N	O
groups	NNS	groups	group	group	N	O
and	CC	and	and	and	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Figures	NNS	figures	figure	figur	N	O
rounded	VBD	rounded	rounded	round	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
nearest	JJS	nearest	nearest	nearest	N	O
integer	NN	integer	integer	integ	N	O
.	.	.	.	.	N	O

Dose	VB	dose	dose	dose	N	O

-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
were	VBD	were	were	were	N	O
twice	RB	twice	twice	twice	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
stiffness	NN	stiffness	stiffness	stiff	Y	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
:	:	:	:	:	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
were	VBD	were	were	were	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
as	RB	as	a	as	N	O
common	JJ	common	common	common	N	O
on	IN	on	on	on	N	O
20	CD	20	20	20	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
as	IN	as	a	as	N	O
on	IN	on	on	on	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	O
Symptoms	NNP	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
EPS	NNP	eps	eps	ep	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
provided	VBN	provided	provided	provid	N	O
information	NN	information	information	inform	N	O
regarding	VBG	regarding	regarding	regard	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
data	NNS	data	data	data	N	O
collected	VBN	collected	collected	collect	N	O
from	IN	from	from	from	N	O
those	DT	those	those	those	N	O
trials	NNS	trials	trial	trial	N	O
showed	VBD	showed	showed	show	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
as	IN	as	a	as	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
Compared	NNP	compared	compared	compar	N	O
to	TO	to	to	to	N	O
Placebo	VB	placebo	placebo	placebo	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Event	NNP	event	event	event	N	O
Term	NNP	term	term	term	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
483	CD	483	483	483	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
391	CD	391	391	391	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
EPS	NNP	eps	eps	ep	N	O
events	NNS	events	event	event	N	O
11.6	CD	11.6	11.6	11.6	N	O
13.5	CD	13.5	13.5	13.5	N	O
15.1	CD	15.1	15.1	15.1	N	O

Akathisia	$	akathisia	akathisia	akathisia	Y	B-AdverseReaction
2.7	CD	2.7	2.7	2.7	N	O
1.7	CD	1.7	1.7	1.7	N	O
2.3	CD	2.3	2.3	2.3	N	O

Bradykinesia	NNP	bradykinesia	bradykinesia	bradykinesia	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0.6	CD	0.6	0.6	0.6	N	O
0.5	CD	0.5	0.5	0.5	N	O

Dyskinesia	NNP	dyskinesia	dyskinesia	dyskinesia	Y	B-AdverseReaction
1.5	CD	1.5	1.5	1.5	N	O
1.7	CD	1.7	1.7	1.7	N	O
1.0	CD	1.0	1.0	1.0	N	O

Dystonia	NNP	dystonia	dystonia	dystonia	Y	B-AdverseReaction
0.7	CD	0.7	0.7	0.7	N	O
1.0	CD	1.0	1.0	1.0	N	O
0.8	CD	0.8	0.8	0.8	N	O

Parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0.2	CD	0.2	0.2	0.2	N	O
0.3	CD	0.3	0.3	0.3	N	O

Tremor	NNP	tremor	tremor	tremor	Y	B-AdverseReaction
1.9	CD	1.9	1.9	1.9	N	O
2.5	CD	2.5	2.5	2.5	N	O
3.1	CD	3.1	3.1	3.1	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Associated	NNP	associated	associated	associ	N	O
with	IN	with	with	with	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Based	VBN	based	based	base	N	O

on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
difference	NN	difference	difference	differ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
between	IN	between	between	between	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
placebo	$	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
types	NNS	types	type	type	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	VB	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Demographic	JJ	demographic	demographic	demograph	N	O
Differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

An	DT	an	an	an	N	O
examination	NN	examination	examination	examin	N	O
of	IN	of	of	of	N	O
population	NN	population	population	popul	N	O
subgroups	NNS	subgroups	subgroup	subgroup	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
reveal	VB	reveal	reveal	reveal	N	O
any	DT	any	any	ani	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
safety	NN	safety	safety	safeti	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
basis	NN	basis	basis	basi	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
gender	NN	gender	gender	gender	N	O
or	CC	or	or	or	N	O
race	NN	race	race	race	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Test	NNP	test	test	test	N	O
Abnormalities	NNPS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
differences	NNS	differences	difference	differ	N	O
between	IN	between	between	between	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
hematology	NN	hematology	hematology	hematolog	N	O
,	,	,	,	,	N	O
urinalysis	NN	urinalysis	urinalysis	urinalysi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
serum	JJ	serum	serum	serum	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
1342	CD	1342	1342	1342	N	O
)	)	)	)	)	N	O
iloperidone	NN	iloperidone	iloperidone	iloperidon	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	B-AdverseReaction
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
time	NN	time	time	time	N	O
below	IN	below	below	below	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
extended	JJ	extended	extended	extend	N	I-AdverseReaction
normal	JJ	normal	normal	normal	N	I-AdverseReaction
range	NN	range	range	rang	N	I-AdverseReaction
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
randomization	NN	randomization	randomization	random	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
585	CD	585	585	585	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
extended	JJ	extended	extended	extend	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
for	IN	for	for	for	N	O
lowered	JJ	lowered	lowered	lower	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	O
was	VBD	was	wa	wa	N	O
defined	VBN	defined	defined	defin	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
value	NN	value	value	valu	N	O
15%	CD	15%	15%	15%	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
centralized	JJ	centralized	centralized	central	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
that	WDT	that	that	that	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
Premarketing	NNP	premarketing	premarketing	premarket	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O

The	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
terms	NNS	terms	term	term	N	O
that	WDT	that	that	that	N	O
reflect	VBP	reflect	reflect	reflect	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
multiple	JJ	multiple	multiple	multipl	N	O
doses	NNS	doses	dos	dose	N	O
4	CD	4	4	4	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
during	IN	during	during	dure	N	O
any	DT	any	any	ani	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
database	NN	database	database	databas	N	O
of	IN	of	of	of	N	O
3210	CD	3210	3210	3210	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
reported	VBD	reported	reported	report	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
included	VBN	included	included	includ	N	O
except	IN	except	except	except	N	O
those	DT	those	those	those	N	O
already	RB	already	already	alreadi	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
parts	NNS	parts	part	part	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
section	NN	section	section	section	N	O
,	,	,	,	,	N	O
those	DT	those	those	those	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
those	DT	those	those	those	N	O
reaction	NN	reaction	reaction	reaction	N	O
terms	NNS	terms	term	term	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
so	RB	so	so	so	N	O
general	JJ	general	general	gener	N	O
as	IN	as	a	as	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
uninformative	JJ	uninformative	uninformative	uninform	N	O
,	,	,	,	,	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
fewer	JJR	fewer	fewer	fewer	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
neither	DT	neither	neither	neither	N	O
serious	JJ	serious	serious	seriou	N	O
nor	CC	nor	nor	nor	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
,	,	,	,	,	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
otherwise	RB	otherwise	otherwise	otherwis	N	O
common	JJ	common	common	common	N	O
as	IN	as	a	as	N	O
background	NN	background	background	background	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
reactions	NNS	reactions	reaction	reaction	N	O
considered	VBN	considered	considered	consid	N	O
unlikely	JJ	unlikely	unlikely	unlik	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
drug	NN	drug	drug	drug	N	O
related	VBN	related	related	relat	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
emphasize	VB	emphasize	emphasize	emphas	N	O
that	IN	that	that	that	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
occurred	JJ	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
,	,	,	,	,	N	O
they	PRP	they	they	they	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
necessarily	RB	necessarily	necessarily	necessarili	N	O
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
it	PRP	it	it	it	N	O
.	.	.	.	.	N	O

Reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
further	JJ	further	further	further	N	O
categorized	VBN	categorized	categorized	categor	N	O
by	IN	by	by	by	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
definitions	NNS	definitions	definition	definit	N	O
:	:	:	:	:	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
100	CD	100	100	100	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
only	RB	only	only	onli	N	O
those	DT	those	those	those	N	O
not	RB	not	not	not	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
appear	NN	appear	appear	appear	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
listing	NN	listing	listing	list	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
infrequent	JJ	infrequent	infrequent	infrequ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
100	CD	100	100	100	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
1000	CD	1000	1000	1000	N	O
patients	NNS	patients	patient	patient	N	O
;	:	;	;	;	N	O
rare	JJ	rare	rare	rare	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
fewer	JJR	fewer	fewer	fewer	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
1000	CD	1000	1000	1000	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
iron	NN	iron	iron	iron	Y	B-AdverseReaction
deficiency	NN	deficiency	deficiency	defici	N	I-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
,	,	,	,	,	N	O
atrioventricular	JJ	atrioventricular	atrioventricular	atrioventricular	N	B-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
first	RB	first	first	first	N	B-Severity
degree	NN	degree	degree	degre	N	I-Severity
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
congestive	NN	congestive	congestive	congest	N	I-AdverseReaction
and	CC	and	and	and	N	O
acute	NN	acute	acute	acut	N	I-AdverseReaction
)	)	)	)	)	N	O

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
Labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
tinnitus	NN	tinnitus	tinnitus	tinnitu	Y	B-AdverseReaction

Endocrine	NN	endocrine	endocrine	endocrin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
allergic	NN	allergic	allergic	allerg	N	I-AdverseReaction
)	)	)	)	)	N	O
;	:	;	;	;	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
eye	NN	eye	eye	eye	N	I-AdverseReaction
,	,	,	,	,	N	O
blepharitis	NN	blepharitis	blepharitis	blephar	Y	B-AdverseReaction
,	,	,	,	,	N	O
eyelid	JJ	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
lenticular	JJ	lenticular	lenticular	lenticular	N	B-AdverseReaction
opacities	NNS	opacities	opacity	opac	N	I-AdverseReaction
,	,	,	,	,	N	O
cataract	NN	cataract	cataract	cataract	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperemia	NN	hyperemia	hyperemia	hyperemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
conjunctival	NN	conjunctival	conjunctival	conjunctiv	N	I-AdverseReaction
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
salivary	JJ	salivary	salivary	salivari	N	B-AdverseReaction
hypersecretion	NN	hypersecretion	hypersecretion	hypersecret	N	I-AdverseReaction
,	,	,	,	,	N	O
fecal	JJ	fecal	fecal	fecal	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
,	,	,	,	,	N	O
mouth	JJ	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
,	,	,	,	,	N	O
duodenal	JJ	duodenal	duodenal	duoden	N	B-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction
,	,	,	,	,	N	O
hiatus	NN	hiatus	hiatus	hiatu	N	B-AdverseReaction
hernia	NN	hernia	hernia	hernia	Y	I-AdverseReaction
,	,	,	,	,	N	O
hyperchlorhydria	NN	hyperchlorhydria	hyperchlorhydria	hyperchlorhydria	Y	B-AdverseReaction
,	,	,	,	,	N	O
lip	JJ	lip	lip	lip	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
reflux	NN	reflux	reflux	reflux	N	B-AdverseReaction
esophagitis	NN	esophagitis	esophagitis	esophag	Y	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction

General	NNP	general	general	gener	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administrative	NNP	administrative	administrative	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
(	(	(	(	(	N	O
general	JJ	general	general	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
pitting	NN	pitting	pitting	pit	N	I-AdverseReaction
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
cardiac	VB	cardiac	cardiac	cardiac	N	O
disease	NN	disease	disease	diseas	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
difficulty	NN	difficulty	difficulty	difficulti	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
walking	NN	walking	walking	walk	N	I-AdverseReaction
,	,	,	,	,	N	O
thirst	RB	thirst	thirst	thirst	Y	B-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
hyperthermia	NN	hyperthermia	hyperthermia	hyperthermia	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
cholelithiasis	NN	cholelithiasis	cholelithiasis	cholelithiasi	Y	B-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
;	:	;	;	;	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fluid	NN	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	JJ	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
torticollis	NN	torticollis	torticollis	torticolli	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
psychomotor	NN	psychomotor	psychomotor	psychomotor	N	B-AdverseReaction
hyperactivity	NN	hyperactivity	hyperactivity	hyperact	Y	I-AdverseReaction
,	,	,	,	,	N	O
restlessness	NN	restlessness	restlessness	restless	Y	B-AdverseReaction
,	,	,	,	,	N	O
amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nystagmus	RB	nystagmus	nystagmus	nystagmu	Y	B-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
restless	NN	restless	restless	restless	Y	B-AdverseReaction
legs	VBZ	legs	leg	leg	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
restlessness	NN	restlessness	restlessness	restless	Y	B-AdverseReaction
,	,	,	,	,	N	O
aggression	NN	aggression	aggression	aggress	Y	B-AdverseReaction
,	,	,	,	,	N	O
delusion	NN	delusion	delusion	delus	Y	B-AdverseReaction
;	:	;	;	;	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
hostility	NN	hostility	hostility	hostil	Y	B-AdverseReaction
,	,	,	,	,	N	O
libido	NN	libido	libido	libido	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
paranoia	NN	paranoia	paranoia	paranoia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorgasmia	NN	anorgasmia	anorgasmia	anorgasmia	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
mania	NN	mania	mania	mania	Y	B-AdverseReaction
,	,	,	,	,	N	O
catatonia	NN	catatonia	catatonia	catatonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
swings	NNS	swings	swing	swing	N	I-AdverseReaction
,	,	,	,	,	N	O
panic	JJ	panic	panic	panic	N	B-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
,	,	,	,	,	N	O
obsessive	JJ	obsessive	obsessive	obsess	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
compulsive	JJ	compulsive	compulsive	compuls	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
bulimia	NN	bulimia	bulimia	bulimia	Y	B-AdverseReaction
nervosa	NN	nervosa	nervosa	nervosa	N	I-AdverseReaction
,	,	,	,	,	N	O
delirium	NN	delirium	delirium	delirium	Y	B-AdverseReaction
,	,	,	,	,	N	O
polydipsia	NN	polydipsia	polydipsia	polydipsia	Y	B-AdverseReaction
psychogenic	NN	psychogenic	psychogenic	psychogen	N	I-AdverseReaction
,	,	,	,	,	N	O
impulse	JJ	impulse	impulse	impuls	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
control	NN	control	control	control	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
major	JJ	major	major	major	N	B-AdverseReaction
depression	NN	depression	depression	depress	Y	I-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
incontinence	NN	incontinence	incontinence	incontin	Y	I-AdverseReaction
;	:	;	;	;	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
dysuria	NN	dysuria	dysuria	dysuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
pollakiuria	NN	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
enuresis	NN	enuresis	enuresis	enuresi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephrolithiasis	NN	nephrolithiasis	nephrolithiasis	nephrolithiasi	Y	B-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
acute	NN	acute	acute	acut	N	I-AdverseReaction

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
System	NNP	system	system	system	N	O
and	CC	and	and	and	N	O
Breast	NNP	breast	breast	breast	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
-	:	-	-	-	N	O
erectile	JJ	erectile	erectile	erectil	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
;	:	;	;	;	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
testicular	NN	testicular	testicular	testicular	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
menstruation	NN	menstruation	menstruation	menstruat	N	B-AdverseReaction
irregular	NN	irregular	irregular	irregular	N	I-AdverseReaction
,	,	,	,	,	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
,	,	,	,	,	N	O
menorrhagia	NN	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
metrorrhagia	NN	metrorrhagia	metrorrhagia	metrorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
postmenopausal	JJ	postmenopausal	postmenopausal	postmenopaus	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
prostatitis	NN	prostatitis	prostatitis	prostat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Infrequent	NNP	infrequent	infrequent	infrequ	N	O
-	:	-	-	-	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthma	NN	asthma	asthma	asthma	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinorrhea	NN	rhinorrhea	rhinorrhea	rhinorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinus	JJ	sinus	sinus	sinu	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
dryness	NN	dryness	dryness	dryness	N	I-AdverseReaction
;	:	;	;	;	N	O
Rare	NNP	rare	rare	rare	N	O
-	:	-	-	-	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
throat	NN	throat	throat	throat	N	I-AdverseReaction
,	,	,	,	,	N	O
sleep	JJ	sleep	sleep	sleep	N	B-AdverseReaction
apnea	NN	apnea	apnea	apnea	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	VBP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	JJ	exertional	exertional	exert	N	I-AdverseReaction

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
:	:	:	:	:	N	O
retrograde	NN	retrograde	retrograde	retrograd	N	B-AdverseReaction
ejaculation	NN	ejaculation	ejaculation	ejacul	N	I-AdverseReaction
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
MORTALITY	NNP	mortality	mortality	mortal	N	B-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
MORTALITY	NNP	mortality	mortality	mortal	N	B-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Elderly	NNP	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
seventeen	JJ	seventeen	seventeen	seventeen	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
modal	JJ	modal	modal	modal	N	O
duration	NN	duration	duration	durat	N	O
10	CD	10	10	10	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
largely	RB	largely	largely	larg	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
revealed	VBD	revealed	revealed	reveal	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
between	IN	between	between	between	N	O
1.6	CD	1.6	1.6	1.6	N	O
to	TO	to	to	to	N	O
1.7	CD	1.7	1.7	1.7	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
typical	JJ	typical	typical	typic	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
about	IN	about	about	about	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
about	IN	about	about	about	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
varied	VBN	varied	varied	vari	N	O
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
either	RB	either	either	either	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
infectious	JJ	infectious	infectious	infecti	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
nature	NN	nature	nature	natur	N	O
.	.	.	.	.	N	O

Observational	JJ	observational	observational	observ	N	O
studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
,	,	,	,	,	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
conventional	JJ	conventional	conventional	convent	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
mortality	NN	mortality	mortality	mortal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
extent	NN	extent	extent	extent	N	O
to	TO	to	to	to	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
findings	NNS	findings	finding	find	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	O
mortality	NN	mortality	mortality	mortal	N	O
in	IN	in	in	in	N	O
observational	JJ	observational	observational	observ	N	O
studies	NNS	studies	study	studi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drug	NN	drug	drug	drug	N	O
as	IN	as	a	as	N	O
opposed	VBN	opposed	opposed	oppos	N	O
to	TO	to	to	to	N	O
some	DT	some	some	some	N	O
characteristic	JJ	characteristic	characteristic	characterist	N	O
(	(	(	(	(	N	O
s	JJ	s	s	s	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
clear	JJ	clear	clear	clear	N	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dementia	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Psychosis	NN	psychosis	psychosis	psychosi	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NNP	)]	)]	)]	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
MORTALITY	NNP	mortality	mortality	mortal	N	B-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
and	CC	and	and	and	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

QT	JJ	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
Prolongs	NNS	prolongs	prolongs	prolong	N	B-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
-	:	-	-	-	N	O
consider	NN	consider	consider	consid	N	O
using	VBG	using	using	use	N	O
other	JJ	other	other	other	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
first	RB	first	first	first	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
;	:	;	;	;	N	O
use	NN	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
dose	JJ	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	IN	that	that	that	N	O
inhibit	NN	inhibit	inhibit	inhibit	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
metabolism	NN	metabolism	metabolism	metabol	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
serum	NN	serum	serum	serum	N	O
potassium	NN	potassium	potassium	potassium	Y	O
and	CC	and	and	and	N	O
magnesium	NN	magnesium	magnesium	magnesium	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
7.1	CD	7.1	7.1	7.1	N	O
,	,	,	,	,	N	O
7.3	CD	7.3	7.3	7.3	N	O
,	,	,	,	,	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O

Neuroleptic	JJ	neuroleptic	neuroleptic	neurolept	N	B-AdverseReaction
Malignant	NNP	malignant	malignant	malign	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
:	:	:	:	:	N	O
Manage	NN	manage	manage	manag	N	O
with	IN	with	with	with	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NN	discontinue	discontinue	discontinu	N	O
if	IN	if	if	if	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	B-AdverseReaction
mellitus	NNS	mellitus	mellitus	mellitu	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
including	VBG	including	including	includ	N	O
polydipsia	NN	polydipsia	polydipsia	polydipsia	Y	O
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	O
,	,	,	,	,	N	O
polyphagia	NN	polyphagia	polyphagia	polyphagia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weakness	NN	weakness	weakness	weak	Y	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
glucose	VBD	glucose	glucose	glucos	Y	O
regularly	RB	regularly	regularly	regularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Undesirable	JJ	undesirable	undesirable	undesir	N	O
alterations	NNS	alterations	alteration	alter	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Weight	JJ	weight	weight	weight	Y	B-AdverseReaction
Gain	NN	gain	gain	gain	N	I-AdverseReaction
:	:	:	:	:	N	O
Weight	NNP	weight	weight	weight	Y	O
gain	NN	gain	gain	gain	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
weight	NN	weight	weight	weight	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
Changes	NNS	changes	change	chang	N	I-AdverseReaction
:	:	:	:	:	N	O
Atypical	NNP	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
changes	NNS	changes	change	chang	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
risk	NN	risk	risk	risk	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	VBD	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
:	:	:	:	:	N	O
Use	NNP	use	use	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
lower	JJR	lower	lower	lower	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
:	:	:	:	:	N	O
Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
standing	NN	standing	standing	stand	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	B-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
low	JJ	low	low	low	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
)	)	)	)	)	N	O
monitored	VBD	monitored	monitored	monitor	N	O
frequently	RB	frequently	frequently	frequent	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
decline	NN	decline	decline	declin	N	O
in	IN	in	in	in	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
causative	JJ	causative	causative	caus	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
:	:	:	:	:	N	O
Close	JJ	close	close	close	N	O
supervision	NN	supervision	supervision	supervis	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
risk	NN	risk	risk	risk	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O

Priapism	NN	priapism	priapism	priapism	Y	B-AdverseReaction
:	:	:	:	:	N	O
Cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)	)	)	)	)	N	O

Potential	NNP	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
and	CC	and	and	and	N	O
motor	JJ	motor	motor	motor	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
operating	VBG	operating	operating	oper	N	O
machinery	NN	machinery	machinery	machineri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.14	CD	5.14	5.14	5.14	N	O
)	)	)	)	)	N	O

See	VB	see	see	see	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
additional	JJ	additional	additional	addit	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Increased	VBN	increased	increased	increas	N	O

Risks	NNS	risks	risk	risk	N	O
in	IN	in	in	in	N	O
Elderly	JJ	elderly	elderly	elderli	Y	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dementia	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Psychosis	NN	psychosis	psychosis	psychosi	Y	O

Increased	VBN	increased	increased	increas	N	O
Mortality	NN	mortality	mortality	mortal	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
[	NNP	[	[	[	N	O
s	NN	s	s	s	N	O
ee	NN	ee	ee	ee	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

Cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
Including	VBG	including	including	includ	N	O
Stroke	NN	stroke	stroke	stroke	Y	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
risperidone	NN	risperidone	risperidone	risperidon	N	O
,	,	,	,	,	N	O
aripiprazole	NN	aripiprazole	aripiprazole	aripiprazol	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
olanzapine	NN	olanzapine	olanzapine	olanzapin	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	NN	dementia	dementia	dementia	Y	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
accidents	NNS	accidents	accident	accid	N	I-AdverseReaction
and	CC	and	and	and	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attacks	NNS	attacks	attack	attack	N	I-AdverseReaction
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
fatalities	NNS	fatalities	fatality	fatal	N	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
[	NNP	[	[	[	N	O
s	NN	s	s	s	N	O
ee	NN	ee	ee	ee	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
QT	NNP	qt	qt	qt	N	O
Prolongation	NN	prolongation	prolongation	prolong	N	O

In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
or	CC	or	or	or	N	O
schizoaffective	JJ	schizoaffective	schizoaffective	schizoaffect	N	O
disorder	NN	disorder	disorder	disord	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
160	CD	160	160	160	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
msec	NN	msec	msec	msec	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
iloperidone	NN	iloperidone	iloperidone	iloperidon	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
was	VBD	was	wa	wa	N	O
augmented	VBN	augmented	augmented	augment	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
CYP450	NNP	cyp450	cyp450	cyp450	N	O
2	CD	2	2	2	N	O
D6	NNP	d6	d6	d6	N	O
or	CC	or	or	or	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
(	(	(	(	(	N	O
paroxetine	JJ	paroxetine	paroxetine	paroxetin	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
and	CC	and	and	and	N	O
ketoconazole	JJ	ketoconazole	ketoconazole	ketoconazol	N	O
200	CD	200	200	200	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Under	IN	under	under	under	N	O
conditions	NNS	conditions	condition	condit	N	O
of	IN	of	of	of	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
2	CD	2	2	2	N	O
D6	NNP	d6	d6	d6	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
12	CD	12	12	12	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	B-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	O
about	IN	about	about	about	N	O
19	CD	19	19	19	N	O
msec	NNS	msec	msec	msec	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
torsade	NN	torsade	torsade	torsad	N	B-AdverseReaction
de	FW	de	de	de	N	I-AdverseReaction
pointes	NNS	pointes	pointes	point	N	I-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
program	NN	program	program	program	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
including	VBG	including	including	includ	N	O
Class	NNP	class	class	class	N	O
1	CD	1	1	1	N	O
A	NNP	a	a	a	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
,	,	,	,	,	N	O
procainamide	NN	procainamide	procainamide	procainamid	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Class	NNP	class	class	class	N	O
III	NNP	iii	iii	iii	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
amiodarone	NN	amiodarone	amiodarone	amiodaron	N	O
,	,	,	,	,	N	O
sotalol	NN	sotalol	sotalol	sotalol	N	O
)	)	)	)	)	N	O
antiarrhythmic	JJ	antiarrhythmic	antiarrhythmic	antiarrhythm	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
medications	NNS	medications	medication	medic	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
chlorpromazine	NN	chlorpromazine	chlorpromazine	chlorpromazin	N	O
,	,	,	,	,	N	O
thioridazine	NN	thioridazine	thioridazine	thioridazin	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
gatifloxacin	NN	gatifloxacin	gatifloxacin	gatifloxacin	N	O
,	,	,	,	,	N	O
moxifloxacin	NN	moxifloxacin	moxifloxacin	moxifloxacin	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
class	NN	class	class	class	N	O
of	IN	of	of	of	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
pentamidine	NN	pentamidine	pentamidine	pentamidin	N	O
,	,	,	,	,	N	O
levomethadyl	JJ	levomethadyl	levomethadyl	levomethadyl	N	O
acetate	NN	acetate	acetate	acet	N	O
,	,	,	,	,	N	O
methadone	NN	methadone	methadone	methadon	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
.	.	.	.	.	N	O

Certain	NNP	certain	certain	certain	N	O
circumstances	NNS	circumstances	circumstance	circumst	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
torsade	NN	torsade	torsade	torsad	N	O
de	FW	de	de	de	N	O
pointes	NNS	pointes	pointes	point	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
sudden	JJ	sudden	sudden	sudden	N	O
death	NN	death	death	death	Y	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
;	:	;	;	;	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
;	:	;	;	;	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
congenital	JJ	congenital	congenital	congenit	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
;	:	;	;	;	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
recent	JJ	recent	recent	recent	N	O
acute	JJ	acute	acute	acut	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
uncompensated	VBD	uncompensated	uncompensated	uncompens	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

Caution	NN	caution	caution	caution	N	O
is	VBZ	is	is	is	N	O
warranted	VBN	warranted	warranted	warrant	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
with	IN	with	with	with	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
inhibit	VBP	inhibit	inhibit	inhibit	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
metabolism	NN	metabolism	metabolism	metabol	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interaction	NNP	interaction	interaction	interact	N	O
s	NN	s	s	s	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
reduced	JJ	reduced	reduced	reduc	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
CYP2D6	NNP	cyp2d6	cyp2d6	cyp2d6	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
being	VBG	being	being	be	N	O
considered	VBN	considered	considered	consid	N	O
for	IN	for	for	for	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
treatment	NN	treatment	treatment	treatment	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
significant	JJ	significant	significant	signific	N	O
electrolyte	NN	electrolyte	electrolyte	electrolyt	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
have	VBP	have	have	have	N	O
baseline	VBN	baseline	baseline	baselin	N	O
serum	JJ	serum	serum	serum	N	O
potassium	NN	potassium	potassium	potassium	Y	O
and	CC	and	and	and	N	O
magnesium	NN	magnesium	magnesium	magnesium	Y	O
measurements	NNS	measurements	measurement	measur	N	O
with	IN	with	with	with	N	O
periodic	JJ	periodic	periodic	period	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	O
(	(	(	(	(	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
QT	NNP	qt	qt	qt	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
and	CC	and	and	and	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
histories	NNS	histories	history	histori	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
illness	NN	illness	illness	ill	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
QT	NNP	qt	qt	qt	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
,	,	,	,	,	N	O
recent	JJ	recent	recent	recent	N	O
acute	JJ	acute	acute	acut	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
uncompensated	JJ	uncompensated	uncompensated	uncompens	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
persistent	JJ	persistent	persistent	persist	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
measurements	NNS	measurements	measurement	measur	N	O
500	CD	500	500	500	N	O
msec	NN	msec	msec	msec	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
experience	NN	experience	experience	experi	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
could	MD	could	could	could	N	O
indicate	VB	indicate	indicate	indic	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	O
,	,	,	,	,	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
syncope	NN	syncope	syncope	syncop	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
prescriber	NN	prescriber	prescriber	prescrib	N	O
should	MD	should	should	should	N	O
initiate	VB	initiate	initiate	initi	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Neuroleptic	JJ	neuroleptic	neuroleptic	neurolept	N	O
Malignant	NNP	malignant	malignant	malign	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
NMS	NNP	nms	nm	nm	N	O
)	)	)	)	)	N	O

A	DT	a	a	a	N	O
potentially	RB	potentially	potentially	potenti	N	O
fatal	JJ	fatal	fatal	fatal	N	O
symptom	NN	symptom	symptom	symptom	N	O
complex	JJ	complex	complex	complex	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
referred	VBN	referred	referred	refer	N	O
to	TO	to	to	to	N	O
as	IN	as	a	as	N	O
Neuroleptic	NNP	neuroleptic	neuroleptic	neurolept	N	B-AdverseReaction
Malignant	NNP	malignant	malignant	malign	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
NMS	NNP	nms	nm	nm	N	B-AdverseReaction
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
include	VBP	include	include	includ	N	O
hyperpyrexia	NN	hyperpyrexia	hyperpyrexia	hyperpyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
rigidity	NN	rigidity	rigidity	rigid	Y	I-AdverseReaction
,	,	,	,	,	N	O
altered	VBD	altered	altered	alter	N	B-AdverseReaction
mental	JJ	mental	mental	mental	N	I-AdverseReaction
status	NN	status	status	statu	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
catatonic	JJ	catatonic	catatonic	cataton	Y	B-AdverseReaction
signs	NNS	signs	sign	sign	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
autonomic	JJ	autonomic	autonomic	autonom	N	B-AdverseReaction
instability	NN	instability	instability	instabl	N	I-AdverseReaction
(	(	(	(	(	N	O
irregular	JJ	irregular	irregular	irregular	N	B-AdverseReaction
pulse	NN	pulse	pulse	puls	N	I-AdverseReaction
or	CC	or	or	or	N	O
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diaphoresis	NN	diaphoresis	diaphoresis	diaphoresi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
dysrhythmia	NN	dysrhythmia	dysrhythmia	dysrhythmia	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O
signs	NNS	signs	sign	sign	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
creatine	JJ	creatine	creatine	creatin	Y	I-AdverseReaction
phosphokinase	NN	phosphokinase	phosphokinase	phosphokinas	N	I-AdverseReaction
,	,	,	,	,	N	O
myoglobinuria	NN	myoglobinuria	myoglobinuria	myoglobinuria	Y	B-AdverseReaction
(	(	(	(	(	N	O
rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
this	DT	this	this	thi	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
is	VBZ	is	is	is	N	O
complicated	VBN	complicated	complicated	complic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
arriving	VBG	arriving	arriving	arriv	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
identify	VB	identify	identify	identifi	N	O
cases	NNS	cases	case	case	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
presentation	NN	presentation	presentation	present	N	O
includes	VBZ	includes	includes	includ	N	O
both	DT	both	both	both	N	O
serious	JJ	serious	serious	seriou	N	O
medical	JJ	medical	medical	medic	N	O
illness	NN	illness	illness	ill	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
,	,	,	,	,	N	O
systemic	JJ	systemic	systemic	system	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
etc	FW	etc	etc	etc	N	O
.	.	.	.	.	N	O
)	)	)	)	)	N	O

and	CC	and	and	and	N	O
untreated	VBD	untreated	untreated	untreat	N	O
or	CC	or	or	or	N	O
inadequately	RB	inadequately	inadequately	inadequ	N	O
treated	JJ	treated	treated	treat	N	O
extrapyramidal	JJ	extrapyramidal	extrapyramidal	extrapyramid	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
EPS	NNP	eps	eps	ep	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
important	JJ	important	important	import	N	O
considerations	NNS	considerations	consideration	consider	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
include	VBP	include	include	includ	N	O
central	JJ	central	central	central	N	O
anticholinergic	JJ	anticholinergic	anticholinergic	anticholinerg	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
heat	NN	heat	heat	heat	N	O
stroke	NN	stroke	stroke	stroke	Y	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
primary	JJ	primary	primary	primari	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
(	(	(	(	(	N	O
CNS	NNP	cns	cns	cn	N	O
)	)	)	)	)	N	O
pathology	NN	pathology	pathology	patholog	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
not	RB	not	not	not	N	O
essential	JJ	essential	essential	essenti	N	O
to	TO	to	to	to	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
intensive	JJ	intensive	intensive	intens	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
medical	JJ	medical	medical	medic	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
serious	JJ	serious	serious	seriou	N	O
medical	JJ	medical	medical	medic	N	O
problems	NNS	problems	problem	problem	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
specific	JJ	specific	specific	specif	N	O
treatments	NNS	treatments	treatment	treatment	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
general	JJ	general	general	gener	N	O
agreement	NN	agreement	agreement	agreement	N	O
about	IN	about	about	about	N	O
specific	JJ	specific	specific	specif	N	O
pharmacological	JJ	pharmacological	pharmacological	pharmacolog	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimens	NNS	regimens	regimen	regimen	N	O
for	IN	for	for	for	N	O
NMS	NNP	nms	nm	nm	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
requires	VBZ	requires	requires	requir	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drug	NN	drug	drug	drug	N	O
treatment	NN	treatment	treatment	treatment	N	O
after	IN	after	after	after	N	O
recovery	NN	recovery	recovery	recoveri	N	O
from	IN	from	from	from	N	O
NMS	NNP	nms	nm	nm	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
reintroduction	NN	reintroduction	reintroduction	reintroduct	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
,	,	,	,	,	N	O
since	IN	since	since	sinc	N	O
recurrences	NNS	recurrences	recurrence	recurr	N	O
of	IN	of	of	of	N	O
NMS	NNP	nms	nm	nm	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Tardive	JJ	tardive	tardive	tardiv	N	O
Dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O

Tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
syndrome	JJ	syndrome	syndrome	syndrom	N	O
consisting	NN	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
potentially	RB	potentially	potentially	potenti	N	O
irreversible	JJ	irreversible	irreversible	irrevers	N	O
,	,	,	,	,	N	O
involuntary	JJ	involuntary	involuntary	involuntari	N	B-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
dyskinetic	JJ	dyskinetic	dyskinetic	dyskinet	N	I-AdverseReaction
movements	NNS	movements	movement	movement	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
develop	VB	develop	develop	develop	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
appears	VBZ	appears	appears	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
highest	JJS	highest	highest	highest	N	O
among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
women	NNS	women	woman	women	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
impossible	JJ	impossible	impossible	imposs	N	O
to	TO	to	to	to	N	O
rely	VB	rely	rely	reli	N	O
on	IN	on	on	on	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
estimates	NNS	estimates	estimate	estim	N	O
to	TO	to	to	to	N	O
predict	VB	predict	predict	predict	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
inception	NN	inception	inception	incept	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Whether	NNP	whether	whether	whether	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drug	NN	drug	drug	drug	N	O
products	NNS	products	product	product	N	O
differ	VBP	differ	differ	differ	N	O
in	IN	in	in	in	N	O
their	PRP$	their	their	their	N	O
potential	JJ	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
tardive	JJ	tardive	tardive	tardiv	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
tardive	JJ	tardive	tardive	tardiv	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
likelihood	NN	likelihood	likelihood	likelihood	N	O
that	IN	that	that	that	N	O
it	PRP	it	it	it	N	O
will	MD	will	will	will	N	O
become	VB	become	become	becom	N	O
irreversible	JJ	irreversible	irreversible	irrevers	N	O
are	VBP	are	are	are	N	O
believed	VBN	believed	believed	believ	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
administered	JJ	administered	administered	administ	N	O
increases	NNS	increases	increase	increas	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
can	MD	can	can	can	N	O
develop	VB	develop	develop	develop	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
much	JJ	much	much	much	N	O
less	JJR	less	le	less	N	O
commonly	RB	commonly	commonly	commonli	N	O
,	,	,	,	,	N	O
after	IN	after	after	after	N	O
relatively	RB	relatively	relatively	rel	N	O
brief	JJ	brief	brief	brief	N	O
treatment	NN	treatment	treatment	treatment	N	O
periods	NNS	periods	period	period	N	O
at	IN	at	at	at	N	O
low	JJ	low	low	low	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
known	JJ	known	known	known	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
established	VBN	established	established	establish	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
tardive	JJ	tardive	tardive	tardiv	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
may	MD	may	may	may	N	O
remit	VB	remit	remit	remit	N	O
,	,	,	,	,	N	O
partially	RB	partially	partially	partial	N	O
or	CC	or	or	or	N	O
completely	RB	completely	completely	complet	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
.	.	.	.	.	N	O

Antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
itself	PRP	itself	itself	itself	N	O
,	,	,	,	,	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
suppress	VB	suppress	suppress	suppress	N	O
(	(	(	(	(	N	O
or	CC	or	or	or	N	O
partially	RB	partially	partially	partial	N	O
suppress	JJ	suppress	suppress	suppress	N	O
)	)	)	)	)	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
and	CC	and	and	and	N	O
thereby	NN	thereby	thereby	therebi	N	O
may	MD	may	may	may	N	O
possibly	RB	possibly	possibly	possibl	N	O
mask	VB	mask	mask	mask	N	O
the	DT	the	the	the	N	O
underlying	JJ	underlying	underlying	underli	N	O
process	NN	process	process	process	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
that	IN	that	that	that	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
suppression	NN	suppression	suppression	suppress	N	O
has	VBZ	has	ha	ha	N	O
upon	IN	upon	upon	upon	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
these	DT	these	these	these	N	O
considerations	NNS	considerations	consideration	consider	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
manner	NN	manner	manner	manner	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
most	RBS	most	most	most	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
tardive	JJ	tardive	tardive	tardiv	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
generally	RB	generally	generally	gener	N	O
be	VB	be	be	be	N	O
reserved	VBN	reserved	reserved	reserv	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
suffer	VBP	suffer	suffer	suffer	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
chronic	JJ	chronic	chronic	chronic	N	O
illness	NN	illness	illness	ill	N	O
that	WDT	that	that	that	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
respond	VB	respond	respond	respond	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
whom	WP	whom	whom	whom	N	O
alternative	JJ	alternative	alternative	altern	N	O
,	,	,	,	,	N	O
equally	RB	equally	equally	equal	N	O
effective	JJ	effective	effective	effect	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
potentially	RB	potentially	potentially	potenti	N	O
less	JJR	less	le	less	N	O
harmful	JJ	harmful	harmful	harm	N	O
treatments	NNS	treatments	treatment	treatment	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
or	CC	or	or	or	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
do	VBP	do	do	do	N	O
require	VB	require	require	requir	N	O
chronic	JJ	chronic	chronic	chronic	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
smallest	JJS	smallest	smallest	smallest	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
shortest	JJS	shortest	shortest	shortest	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
producing	VBG	producing	producing	produc	N	O
a	DT	a	a	a	N	O
satisfactory	JJ	satisfactory	satisfactory	satisfactori	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
sought	VBN	sought	sought	sought	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
need	NN	need	need	need	N	O
for	IN	for	for	for	N	O
continued	JJ	continued	continued	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reassessed	VBN	reassessed	reassessed	reassess	N	O
periodically	RB	periodically	periodically	period	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
tardive	JJ	tardive	tardive	tardiv	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O
appear	VBP	appear	appear	appear	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
despite	IN	despite	despite	despit	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Metabolic	NNP	metabolic	metabolic	metabol	N	O
Changes	NNS	changes	change	chang	N	O

Atypical	NNP	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
changes	NNS	changes	change	chang	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	B-AdverseReaction
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	I-AdverseReaction
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	I-AdverseReaction
risk	NN	risk	risk	risk	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
changes	NNS	changes	change	chang	N	O
include	VBP	include	include	includ	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
body	NN	body	body	bodi	N	B-AdverseReaction
weight	JJ	weight	weight	weight	Y	I-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Patient	NNP	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17.3	CD	17.3	17.3	17.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
all	DT	all	all	all	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
some	DT	some	some	some	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	O
changes	NNS	changes	change	chang	N	O
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
drug	NN	drug	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
class	NN	class	class	class	N	O
has	VBZ	has	ha	ha	N	O
its	PRP$	its	it	it	N	O
own	JJ	own	own	own	N	O
specific	JJ	specific	specific	specif	N	O
risk	NN	risk	risk	risk	N	O
profile	NN	profile	profile	profil	N	O
.	.	.	.	.	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
and	CC	and	and	and	N	O
Diabetes	NNP	diabetes	diabetes	diabet	Y	O
Mellitus	NNP	mellitus	mellitus	mellitu	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
extreme	JJ	extreme	extreme	extrem	N	B-Severity
and	CC	and	and	and	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
hyperosmolar	JJ	hyperosmolar	hyperosmolar	hyperosmolar	N	B-AdverseReaction
coma	NN	coma	coma	coma	Y	I-AdverseReaction
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
including	VBG	including	including	includ	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
.	.	.	.	.	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
is	VBZ	is	is	is	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
background	NN	background	background	background	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
increasing	VBG	increasing	increasing	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	VBP	mellitus	mellitus	mellitu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
these	DT	these	these	these	N	O
confounders	NNS	confounders	confounders	confound	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
completely	RB	completely	completely	complet	N	O
understood	JJ	understood	understood	understood	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
epidemiological	JJ	epidemiological	epidemiological	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
included	VBD	included	included	includ	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
marketed	VBN	marketed	marketed	market	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
performed	VBN	performed	performed	perform	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
if	IN	if	if	if	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
this	DT	this	this	thi	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
established	VBN	established	established	establish	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
started	VBN	started	started	start	N	O
on	IN	on	on	on	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
regularly	RB	regularly	regularly	regularli	N	O
for	IN	for	for	for	N	O
worsening	VBG	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
control	NN	control	control	control	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
obesity	NN	obesity	obesity	obes	Y	O
,	,	,	,	,	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
testing	VBG	testing	testing	test	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
beginning	NN	beginning	beginning	begin	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
including	VBG	including	including	includ	N	O
polydipsia	NN	polydipsia	polydipsia	polydipsia	Y	O
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	O
,	,	,	,	,	N	O
polyphagia	NN	polyphagia	polyphagia	polyphagia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weakness	NN	weakness	weakness	weak	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
testing	NN	testing	testing	test	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
has	VBZ	has	ha	ha	N	O
resolved	VBN	resolved	resolved	resolv	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	NN	antipsychotic	antipsychotic	antipsychot	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
required	VBN	required	required	requir	N	O
continuation	NN	continuation	continuation	continu	N	O
of	IN	of	of	of	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
treatment	NN	treatment	treatment	treatment	N	O
despite	IN	despite	despite	despit	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
suspect	JJ	suspect	suspect	suspect	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
adult	JJ	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
samples	NNS	samples	sample	sampl	N	O
were	VBD	were	were	were	N	O
drawn	VBN	drawn	drawn	drawn	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Glucose	NNP	glucose	glucose	glucos	Y	O

FANAPT	NN	fanapt	fanapt	fanapt	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

n	RB	n	n	n	N	O
114	CD	114	114	114	N	O
n	NNS	n	n	n	N	O
228	CD	228	228	228	N	O

Serum	NNP	serum	serum	serum	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
-	:	-	-	-	N	O
0.5	CD	0.5	0.5	0.5	N	O
6.6	CD	6.6	6.6	6.6	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O

Serum	NNP	serum	serum	serum	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O
Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
2.5	CD	2.5	2.5	2.5	N	O
10.7	CD	10.7	10.7	10.7	N	O

(	(	(	(	(	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
126	CD	126	126	126	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
80	CD	80	80	80	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
169	CD	169	169	169	N	O
)	)	)	)	)	N	O

Pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
including	VBG	including	including	includ	N	O
longer	JJR	longer	longer	longer	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

3	LS	3	3	3	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
1.8	CD	1.8	1.8	1.8	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
773	CD	773	773	773	N	O
)	)	)	)	)	N	O
5.4	CD	5.4	5.4	5.4	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
723	CD	723	723	723	N	O
)	)	)	)	)	N	O
5.4	CD	5.4	5.4	5.4	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
425	CD	425	425	425	N	O
)	)	)	)	)	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
3.6	CD	3.6	3.6	3.6	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
9.0	CD	9.0	9.0	9.0	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
31	CD	31	31	31	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
18.0	CD	18.0	18.0	18.0	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O

Dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	O

Undesirable	JJ	undesirable	undesirable	undesir	N	B-AdverseReaction

alterations	NNS	alterations	alteration	alter	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
lipids	NNS	lipids	lipid	lipid	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
samples	NNS	samples	sample	sampl	N	O
were	VBD	were	were	were	N	O
drawn	VBN	drawn	drawn	drawn	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
adult	JJ	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Fasting	NNP	fasting	fasting	fast	Y	O
Lipids	NNP	lipids	lipid	lipid	Y	O

FANAPT	NN	fanapt	fanapt	fanapt	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
n	VBZ	n	n	n	N	O
114	CD	114	114	114	N	O
n	NN	n	n	n	N	O
228	CD	228	228	228	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
-	:	-	-	-	N	O
2.17	CD	2.17	2.17	2.17	N	O
8.18	CD	8.18	8.18	8.18	N	O

LDL	NNP	ldl	ldl	ldl	Y	O
n	CC	n	n	n	N	O
109	CD	109	109	109	N	O
n	NNS	n	n	n	N	O
217	CD	217	217	217	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
-	:	-	-	-	N	O
1.41	CD	1.41	1.41	1.41	N	O
9.03	CD	9.03	9.03	9.03	N	O

HDL	NNP	hdl	hdl	hdl	Y	O
n	CC	n	n	n	N	O
114	CD	114	114	114	N	O
n	NNS	n	n	n	N	O
228	CD	228	228	228	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
-	:	-	-	-	N	O
3.35	CD	3.35	3.35	3.35	N	O
0.55	CD	0.55	0.55	0.55	N	O

Triglycerides	NNP	triglycerides	triglyceride	triglycerid	Y	O
n	CC	n	n	n	N	O
114	CD	114	114	114	N	O
n	NNS	n	n	n	N	O
228	CD	228	228	228	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
16.47	CD	16.47	16.47	16.47	N	O
-	:	-	-	-	N	O
0.83	CD	0.83	0.83	0.83	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O

Cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
3.6%	CD	3.6%	3.6%	3.6%	N	O

(	(	(	(	(	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
240	CD	240	240	240	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
72	CD	72	72	72	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
141	CD	141	141	141	N	O
)	)	)	)	)	N	O

LDL	NN	ldl	ldl	ldl	Y	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O

(	(	(	(	(	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
160	CD	160	160	160	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
42	CD	42	42	42	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O

HDL	NN	hdl	hdl	hdl	Y	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
Low	NNP	low	low	low	N	O
23.8%	CD	23.8%	23.8%	23.8%	N	O
12.1%	CD	12.1%	12.1%	12.1%	N	O

(	(	(	(	(	N	O
40	CD	40	40	40	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
40	CD	40	40	40	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
80	CD	80	80	80	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
166	CD	166	166	166	N	O
)	)	)	)	)	N	O

Triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
8.3%	CD	8.3%	8.3%	8.3%	N	O
10.1%	CD	10.1%	10.1%	10.1%	N	O

(	(	(	(	(	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
72	CD	72	72	72	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
148	CD	148	148	148	N	O
)	)	)	)	)	N	O

Pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
and	CC	and	and	and	N	O
triglyceride	VB	triglyceride	triglyceride	triglycerid	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
including	VBG	including	including	includ	N	O
longer	JJR	longer	longer	longer	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
4	CD	4	4	4	N	O
and	CC	and	and	and	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

3	LS	3	3	3	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
3.9	CD	3.9	3.9	3.9	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
783	CD	783	783	783	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
3.9	CD	3.9	3.9	3.9	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
726	CD	726	726	726	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
7.7	CD	7.7	7.7	7.7	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
428	CD	428	428	428	N	O
)	)	)	)	)	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
19.4	CD	19.4	19.4	19.4	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
23.2	CD	23.2	23.2	23.2	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
31	CD	31	31	31	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
19.4	CD	19.4	19.4	19.4	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Triglycerides	NNP	triglycerides	triglyceride	triglycerid	Y	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

3	LS	3	3	3	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
8.9	CD	8.9	8.9	8.9	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
783	CD	783	783	783	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
8.9	CD	8.9	8.9	8.9	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
726	CD	726	726	726	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
17.7	CD	17.7	17.7	17.7	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
428	CD	428	428	428	N	O
)	)	)	)	)	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
26.6	CD	26.6	26.6	26.6	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
35.4	CD	35.4	35.4	35.4	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
31	CD	31	31	31	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
17.7	CD	17.7	17.7	17.7	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O

Weight	NNP	weight	weight	weight	Y	O
Gain	NNP	gain	gain	gain	N	O

Weight	NN	weight	weight	weight	Y	B-AdverseReaction

gain	NN	gain	gain	gain	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
weight	NN	weight	weight	weight	Y	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
at	IN	at	at	at	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
was	VBD	was	wa	wa	N	O
2.1	CD	2.1	2.1	2.1	N	O
kg	NN	kg	kg	kg	N	O
.	.	.	.	.	N	O

Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
(	(	(	(	(	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
7%	CD	7%	7%	7%	N	O
gain	NN	gain	gain	gain	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
from	IN	from	from	from	N	O
4	CD	4	4	4	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Body	NNP	body	body	bodi	N	O
Weight	NNP	weight	weight	weight	Y	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
24	CD	24	24	24	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O

n	RB	n	n	n	N	O
576	CD	576	576	576	N	O
n	JJ	n	n	n	N	O
481	CD	481	481	481	N	O
n	JJ	n	n	n	N	O
391	CD	391	391	391	N	O

Weight	NNP	weight	weight	weight	Y	O
(	(	(	(	(	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
-	:	-	-	-	N	O
0.1	CD	0.1	0.1	0.1	N	O
2.0	CD	2.0	2.0	2.0	N	O
2.7	CD	2.7	2.7	2.7	N	O

Weight	NNP	weight	weight	weight	Y	O
Gain	NNP	gain	gain	gain	N	O

7%	CD	7%	7%	7%	N	O
increase	NN	increase	increase	increas	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
4%	CD	4%	4%	4%	N	O
12%	CD	12%	12%	12%	N	O
18%	CD	18%	18%	18%	N	O

5.6	CD	5.6	5.6	5.6	N	O
Seizures	NNS	seizures	seizure	seizur	Y	O

In	IN	in	in	in	N	O

short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
seizures	VBZ	seizures	seizure	seizur	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
1344	CD	1344	1344	1344	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
potentially	RB	potentially	potentially	potenti	N	O
lower	JJR	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
Alzheimer	NNP	alzheimer	alzheimer	alzheim	N	O
's	POS	's	's	's	N	O
dementia	NN	dementia	dementia	dementia	Y	O
.	.	.	.	.	N	O

Conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
lower	VBP	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	JJR	more	more	more	N	O
prevalent	NN	prevalent	prevalent	preval	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
Hypotension	NNP	hypotension	hypotension	hypotens	Y	O
and	CC	and	and	and	N	O
Syncope	NNP	syncope	syncope	syncop	Y	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
can	MD	can	can	can	N	B-Factor
induce	VB	induce	induce	induc	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
reflects	VBZ	reflects	reflects	reflect	N	O
its	PRP$	its	it	it	N	O
alpha1	JJ	alpha1	alpha1	alpha1	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
properties	NNS	properties	property	properti	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
where	WRB	where	where	where	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
slowly	RB	slowly	slowly	slowli	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
above	IN	above	above	abov	N	O
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
1344	CD	1344	1344	1344	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
given	VBN	given	given	given	N	O
20	CD	20	20	20	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
given	VBN	given	given	given	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
given	VBN	given	given	given	N	O
placebo	NNS	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
rapid	JJ	rapid	rapid	rapid	N	O
titration	NN	titration	titration	titrat	N	O
would	MD	would	would	would	N	O
be	VB	be	be	be	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
ischemia	NN	ischemia	ischemia	ischemia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
conduction	NN	conduction	conduction	conduct	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
predispose	VBP	predispose	predispose	predispos	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
to	TO	to	to	to	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
(	(	(	(	(	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	O
,	,	,	,	,	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
vital	JJ	vital	vital	vital	N	O
signs	NNS	signs	sign	sign	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
vulnerable	JJ	vulnerable	vulnerable	vulner	N	O
to	TO	to	to	to	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	O
,	,	,	,	,	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
and	CC	and	and	and	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
neutropenia	NNS	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
temporally	RB	temporally	temporally	tempor	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
.	.	.	.	.	N	O

Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Possible	JJ	possible	possible	possibl	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
include	VBP	include	include	includ	N	O
preexisting	VBG	preexisting	preexisting	preexist	N	O
low	JJ	low	low	low	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
induced	VBN	induced	induced	induc	N	O
leukopenia	JJ	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
low	JJ	low	low	low	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
induced	VBN	induced	induced	induc	N	O
leukopenia	IN	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
)	)	)	)	)	N	O
monitored	VBD	monitored	monitored	monitor	N	O
frequently	RB	frequently	frequently	frequent	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
decline	NN	decline	decline	declin	N	O
in	IN	in	in	in	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
causative	JJ	causative	causative	caus	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
neutropenia	DT	neutropenia	neutropenia	neutropenia	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
treated	VBN	treated	treated	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
(	(	(	(	(	N	O
absolute	JJ	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
1000	CD	1000	1000	1000	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
their	PRP$	their	their	their	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
followed	VBD	followed	followed	follow	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Hyperprolactinemia	NN	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	IN	that	that	that	N	O
antagonize	VBP	antagonize	antagonize	antagon	N	O
dopamine	JJ	dopamine	dopamine	dopamin	N	O
D2	NNP	d2	d2	d2	N	O
receptors	NNS	receptors	receptor	receptor	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
elevates	VBZ	elevates	elevates	elev	N	B-AdverseReaction
prolactin	JJ	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
.	.	.	.	.	N	O

Hyperprolactinemia	NNP	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
suppress	VB	suppress	suppress	suppress	N	B-AdverseReaction
hypothalamic	JJ	hypothalamic	hypothalamic	hypothalam	N	I-AdverseReaction
GnRH	NNP	gnrh	gnrh	gnrh	N	I-AdverseReaction
,	,	,	,	,	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
reduced	JJ	reduced	reduced	reduc	N	B-AdverseReaction
pituitary	JJ	pituitary	pituitary	pituitari	N	I-AdverseReaction
gonadotropin	NN	gonadotropin	gonadotropin	gonadotropin	N	I-AdverseReaction
secretion	NN	secretion	secretion	secret	N	I-AdverseReaction
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
turn	NN	turn	turn	turn	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
inhibit	VB	inhibit	inhibit	inhibit	N	B-AdverseReaction
reproductive	JJ	reproductive	reproductive	reproduct	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
by	IN	by	by	by	N	O
impairing	VBG	impairing	impairing	impair	N	B-AdverseReaction
gonadalsteroidogenesis	NN	gonadalsteroidogenesis	gonadalsteroidogenesis	gonadalsteroidogenesi	N	I-AdverseReaction
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Galactorrhea	NNP	galactorrhea	galactorrhea	galactorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
impotence	NN	impotence	impotence	impot	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
prolactin	NN	prolactin	prolactin	prolactin	Y	B-DrugClass
-	:	-	-	-	N	I-DrugClass
elevating	VBG	elevating	elevating	elev	N	I-DrugClass
compounds	NNS	compounds	compound	compound	N	I-DrugClass
.	.	.	.	.	N	O

Long	NNP	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
standing	NN	standing	standing	stand	N	I-AdverseReaction
hyperprolactinemia	NN	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	I-AdverseReaction
when	WRB	when	when	when	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
hypogonadism	NN	hypogonadism	hypogonadism	hypogonad	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Tissue	NN	tissue	tissue	tissu	N	O
culture	NN	culture	culture	cultur	Y	O
experiments	NNS	experiments	experiment	experi	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
-	:	-	-	-	N	O
third	NN	third	third	third	N	O
of	IN	of	of	of	N	O
human	JJ	human	human	human	N	O
breast	NN	breast	breast	breast	N	O
cancers	NNS	cancers	cancer	cancer	N	O
are	VBP	are	are	are	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
factor	NN	factor	factor	factor	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
importance	NN	importance	importance	import	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
prescription	NN	prescription	prescription	prescript	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
is	VBZ	is	is	is	N	O
contemplated	VBN	contemplated	contemplated	contempl	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
detected	VBN	detected	detected	detect	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

Mammary	JJ	mammary	mammary	mammari	N	B-AdverseReaction
gland	NN	gland	gland	gland	N	I-AdverseReaction
proliferative	JJ	proliferative	proliferative	prolif	N	I-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
and	CC	and	and	and	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
mice	NN	mice	mouse	mice	N	B-Animal
and	CC	and	and	and	N	O
rats	NNS	rats	rat	rat	N	B-Animal
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Nonclinical	JJ	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Neither	DT	neither	neither	neither	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
nor	CC	nor	nor	nor	N	O
epidemiologic	JJ	epidemiologic	epidemiologic	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
conducted	VBN	conducted	conducted	conduct	N	O
to	TO	to	to	to	N	O
date	NN	date	date	date	N	O
have	VB	have	have	have	N	O
shown	VBN	shown	shown	shown	N	O
an	DT	an	an	an	N	O
association	NN	association	association	associ	N	O
between	IN	between	between	between	N	O
chronic	JJ	chronic	chronic	chronic	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
class	NN	class	class	class	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
tumorigenesis	NN	tumorigenesis	tumorigenesis	tumorigenesi	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
available	JJ	available	available	avail	N	O
evidence	NN	evidence	evidence	evid	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
too	RB	too	too	too	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
at	IN	at	at	at	N	O
this	DT	this	this	thi	N	O
time	NN	time	time	time	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
endpoint	VB	endpoint	endpoint	endpoint	N	O
in	IN	in	in	in	N	O
plasma	JJ	plasma	plasma	plasma	N	B-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
24	CD	24	24	24	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
was	VBD	was	wa	wa	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	I-AdverseReaction
of	IN	of	of	of	N	O
2.6	CD	2.6	2.6	2.6	N	B-Severity
ng	JJ	ng	ng	ng	N	I-Severity
mL	NNS	ml	ml	ml	N	I-Severity
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
6.3	CD	6.3	6.3	6.3	N	O
ng	JJ	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
plasma	JJ	plasma	plasma	plasma	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
26%	CD	26%	26%	26%	N	O
of	IN	of	of	of	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
12%	CD	12%	12%	12%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
modest	JJ	modest	modest	modest	N	B-Severity
levels	NNS	levels	level	level	N	I-Severity
of	IN	of	of	of	N	O
prolactin	NN	prolactin	prolactin	prolactin	Y	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
greater	JJR	greater	greater	greater	N	B-Severity
prolactin	JJ	prolactin	prolactin	prolactin	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
some	DT	some	some	some	N	O
other	JJ	other	other	other	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
including	VBG	including	including	includ	N	O
longer	JJR	longer	longer	longer	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
3210	CD	3210	3210	3210	N	O
adults	NNS	adults	adult	adult	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
iloperidone	NN	iloperidone	iloperidone	iloperidon	N	O
,	,	,	,	,	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
male	JJ	male	male	male	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
galactorrhea	NN	galactorrhea	galactorrhea	galactorrhea	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
female	JJ	female	female	femal	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
female	JJ	female	female	femal	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Body	NNP	body	body	bodi	N	O
Temperature	NNP	temperature	temperature	temperatur	N	O
Regulation	NNP	regulation	regulation	regul	N	O

Disruption	NN	disruption	disruption	disrupt	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
ability	NN	ability	ability	abil	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
reduce	VB	reduce	reduce	reduc	N	I-AdverseReaction
core	NN	core	core	core	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
temperature	NN	temperature	temperature	temperatur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
care	NN	care	care	care	N	O
is	VBZ	is	is	is	N	O
advised	VBN	advised	advised	advis	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
will	MD	will	will	will	N	O
be	VB	be	be	be	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
conditions	NNS	conditions	condition	condit	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
elevation	NN	elevation	elevation	elev	N	O
in	IN	in	in	in	N	O
core	NN	core	core	core	N	O
body	NN	body	body	bodi	N	O
temperature	NN	temperature	temperature	temperatur	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
exercising	VBG	exercising	exercising	exercis	N	O
strenuously	RB	strenuously	strenuously	strenuous	N	O
,	,	,	,	,	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
extreme	VB	extreme	extreme	extrem	N	O
heat	NN	heat	heat	heat	N	O
,	,	,	,	,	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medication	NN	medication	medication	medic	N	O
with	IN	with	with	with	N	O
anticholinergic	JJ	anticholinergic	anticholinergic	anticholinerg	N	O
activity	NN	activity	activity	activ	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
being	VBG	being	being	be	N	O
subject	JJ	subject	subject	subject	N	O
to	TO	to	to	to	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	O

Esophageal	NNP	esophageal	esophageal	esophag	N	B-AdverseReaction
dysmotility	NN	dysmotility	dysmotility	dysmotil	N	I-AdverseReaction
and	CC	and	and	and	N	O
aspiration	NN	aspiration	aspiration	aspir	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drug	NN	drug	drug	drug	N	I-DrugClass
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Aspiration	NNP	aspiration	aspiration	aspir	Y	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
common	JJ	common	common	common	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
morbidity	NN	morbidity	morbidity	morbid	N	O
and	CC	and	and	and	N	O
mortality	NN	mortality	mortality	mortal	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
particular	JJ	particular	particular	particular	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
Alzheimer	NNP	alzheimer	alzheimer	alzheim	N	O
's	POS	's	's	's	N	O
dementia	NN	dementia	dementia	dementia	Y	O
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
aspiration	NN	aspiration	aspiration	aspir	Y	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Suicide	NN	suicide	suicide	suicid	Y	O

The	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
suicide	JJ	suicide	suicide	suicid	Y	O
attempt	NN	attempt	attempt	attempt	N	O
is	VBZ	is	is	is	N	O
inherent	JJ	inherent	inherent	inher	N	O
in	IN	in	in	in	N	O
psychotic	JJ	psychotic	psychotic	psychot	Y	O
illness	NN	illness	illness	ill	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
supervision	NN	supervision	supervision	supervis	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
accompany	VB	accompany	accompany	accompani	N	O
drug	NN	drug	drug	drug	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Prescriptions	NNS	prescriptions	prescription	prescript	N	O
for	IN	for	for	for	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
written	VBN	written	written	written	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
smallest	JJS	smallest	smallest	smallest	N	O
quantity	NN	quantity	quantity	quantiti	N	O
of	IN	of	of	of	N	O
tablets	NNS	tablets	tablet	tablet	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
good	JJ	good	good	good	N	O
patient	NN	patient	patient	patient	N	O
management	NN	management	management	manag	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
overdose	NN	overdose	overdose	overdos	Y	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Priapism	NN	priapism	priapism	priapism	Y	O

Three	CD	three	three	three	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
priapism	NN	priapism	priapism	priapism	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
premarketing	NN	premarketing	premarketing	premarket	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
program	NN	program	program	program	N	O
.	.	.	.	.	N	O

Drugs	NNS	drugs	drug	drug	N	B-DrugClass
with	IN	with	with	with	N	I-DrugClass
alpha	JJ	alpha	alpha	alpha	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	I-DrugClass
blocking	VBG	blocking	blocking	block	N	I-DrugClass
effects	NNS	effects	effect	effect	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
induce	VB	induce	induce	induc	N	O
priapism	NN	priapism	priapism	priapism	Y	B-AdverseReaction
.	.	.	.	.	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
shares	NNS	shares	share	share	N	O
this	DT	this	this	thi	N	O
pharmacologic	JJ	pharmacologic	pharmacologic	pharmacolog	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
priapism	NN	priapism	priapism	priapism	Y	B-AdverseReaction
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

5.14	CD	5.14	5.14	5.14	N	O
Potential	NNP	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
Cognitive	NNP	cognitive	cognitive	cognit	N	O
and	CC	and	and	and	N	O
Motor	NNP	motor	motor	motor	N	O
Impairment	NNP	impairment	impairment	impair	N	O

FANAPT	NNP	fanapt	fanapt	fanapt	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
to	TO	to	to	to	N	O
impair	VB	impair	impair	impair	N	B-AdverseReaction
judgment	NN	judgment	judgment	judgment	N	I-AdverseReaction
,	,	,	,	,	N	O
thinking	VBG	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
motor	NN	motor	motor	motor	N	I-AdverseReaction
skills	NNS	skills	skill	skill	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11.9%	CD	11.9%	11.9%	11.9%	N	O
(	(	(	(	(	N	O
104	CD	104	104	104	N	O
874	CD	874	874	874	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
versus	NN	versus	versus	versu	N	O
5.3%	CD	5.3%	5.3%	5.3%	N	O
(	(	(	(	(	N	O
31	CD	31	31	31	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
cautioned	VBN	cautioned	cautioned	caution	N	O
about	IN	about	about	about	N	O
operating	VBG	operating	operating	oper	N	O
hazardous	JJ	hazardous	hazardous	hazard	N	O
machinery	NN	machinery	machinery	machineri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
automobiles	NNS	automobiles	automobile	automobil	N	O
,	,	,	,	,	N	O
until	IN	until	until	until	N	O
they	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
reasonably	RB	reasonably	reasonably	reason	N	O
certain	JJ	certain	certain	certain	N	O
that	IN	that	that	that	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
FANAPT	NNP	fanapt	fanapt	fanapt	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
affect	VB	affect	affect	affect	N	O
them	PRP	them	them	them	N	O
adversely	RB	adversely	adversely	advers	N	O
.	.	.	.	.	N	O

